Adlai Nortye Presents on Molecular Targets at Cancer Conf.
Adlai Nortye will deliver an oral presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on...
PMV Pharma to Present Pivotal Phase 2 Rezatapopt Results
PMV Pharmaceuticals will deliver the first look at initial data from its pivotal Phase 2 PYNNACLE study of rezatapopt...
FDA Extends Review of Denali’s Hunter Syndrome Drug
Denali Therapeutics’ biologics license application for tividenofusp alfa, a brain-penetrant enzyme replacement for Hunter syndrome (MPS II), will undergo...
PMV Pharma to Present Pivotal Phase 2 Rezatapopt Results
PMV Pharmaceuticals will present initial data from its pivotal Phase 2 PYNNACLE study of rezatapopt (PC14586), a first-in-class small...
Salarius Pharmaceuticals’ Successful Nasdaq Compliance Victory
Salarius Pharmaceuticals has regained compliance with Nasdaq’s equity standard, completing its return to full listing compliance after previously restoring...
Palisade Bio Unlocks Canadian Patent for Lead Drug Pali-2108
Palisade Bio has secured a Canadian composition-of-matter patent for PALI-2108, a gut microbiota–activated, ileocolonic-targeted PDE4 B/D inhibitor in development...
Apyx Seeks FDA Label Expansion for Liposuction System
Apyx Medical has submitted a new 510(k) to the FDA seeking a label expansion for its AYON body contouring...
Rentschler Biopharma Sees Progress on New Laupheim Facility
Rentschler Biopharma is building a new buffer media station at its Laupheim, Germany headquarters, the largest single investment the...
Chapper’s Remarkable 50-Year Triumph in Global Pharma
Chapper Healthcare, now AscellaHealth’s global pharmaceutical wholesaler, distributor, and commercialization services arm, is marking its 50th anniversary with a...
Nilo Therapeutics Launches with $101M for Immune Disease Drugs
Nilo Therapeutics has raised a $101 million Series A round and appointed industry veteran Kim Seth as CEO, signaling...